STOCK TITAN

Innate Pharma Sa Stock Price, News & Analysis

IPHA Nasdaq

Welcome to our dedicated page for Innate Pharma Sa news (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma Sa stock.

Innate Pharma SA (IPHA) is a clinical-stage biotechnology leader advancing immuno-oncology therapies through innovative antibody development. This page serves as the definitive source for official company announcements and curated news coverage.

Key updates include clinical trial milestones, regulatory developments, strategic collaborations, and scientific advancements. Investors and researchers will find timely information on NK cell engager therapeutics, partnership expansions with major biopharma entities, and progress across the company's oncology pipeline.

All content is sourced directly from verified corporate communications and reputable financial analysis. Bookmark this page for streamlined access to IPHA's latest developments in harnessing innate immunity for cancer treatment breakthroughs.

Rhea-AI Summary

Innate Pharma (Nasdaq: IPHA) announced that an abstract for IPH4502, their novel topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4, has been selected for presentation at the AACR Annual Meeting 2025 in Chicago.

IPH4502 is currently in Phase 1 clinical trials for advanced solid tumors. The drug has shown preclinical anti-tumor efficacy in models of primary and acquired resistance to enfortumab vedotin, as well as in tumors with low to moderate Nectin-4 expression, suggesting potential applications beyond urothelial carcinoma.

The presentation will take place during a poster session on Tuesday, April 29, 2025. Additionally, CEO Jonathan Dickinson will present an update on Innate's pipeline and strategy at the AACR Oncology Industry Partnering Event on April 24, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.12%
Tags
none
-
Rhea-AI Summary

Innate Pharma (Nasdaq: IPHA) has announced its upcoming participation in the Life Sciences Van Lanschot Kempen Conference. The event is scheduled to take place in Amsterdam, Netherlands, from April 1-3, 2025. Members of the company's executive team will be attending this investor conference.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.13%
Tags
none
-
Rhea-AI Summary

Innate Pharma (Nasdaq: IPHA) has scheduled a conference call and webcast to discuss its full year 2024 financial results on Thursday, March 27, 2025 at 2 p.m. CET / 9 a.m. EDT.

Key executives participating in the call will include Jonathan Dickinson (CEO), Sonia Quaratino (EVP, Chief Medical Officer), Yannis Morel (EVP, Chief Operating Officer), and Frédéric Lombard (SVP, Chief Financial Officer).

The webcast will be accessible through the company's website, with a replay available for 90 days following the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.21%
Tags
conferences earnings
Rhea-AI Summary

Innate Pharma (Nasdaq: IPHA) has announced its participation in the upcoming Leerink Partners 2025 Global Healthcare Conference in Miami, Florida. The event will take place at the W Hotel South Beach from March 10-12, 2025.

The company's executive team will engage in two key activities during the conference: conducting one-on-one meetings with attendees and participating in a fireside chat scheduled for Tuesday, March 11, 2025, from 3:00 to 3:30 pm ET. Both a live webcast and replay of the presentation will be accessible through the Events page in the Investors section of Innate Pharma's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.42%
Tags
conferences
-
Rhea-AI Summary

Innate Pharma announced that the U.S. FDA has granted Breakthrough Therapy Designation (BTD) to lacutamab for treating adult patients with relapsed or refractory Sézary Syndrome after at least 2 prior systemic therapies including mogamulizumab. The designation is based on Phase 1 and Phase 2 TELLOMAK study results, which showed encouraging efficacy and favorable safety profile in heavily pretreated patients.

The BTD aims to accelerate development and regulatory review of drugs treating serious conditions. This adds to lacutamab's previous Fast Track designation (2019) and PRIME designation by European Medicines Agency (2020). The company is currently aligning with regulatory agencies regarding a confirmatory Phase 3 trial in Cutaneous T Cell Lymphoma and seeking a partnership.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Innate Pharma has announced the dosing of the first patient in its Phase 1 study of IPH4502, a novel antibody-drug conjugate (ADC) targeting Nectin-4, in patients with advanced solid tumors. The study (NCT06781983) will evaluate the safety, tolerability, and preliminary efficacy of IPH4502 as a single agent.

The trial consists of two parts: Part 1 Dose Escalation and Part 2 Dose Optimization, planning to enroll approximately 105 patients. The study targets tumors known to express Nectin-4, including urothelial carcinoma, breast cancer, non-small cell lung cancer, and gastro-intestinal cancer.

IPH4502 is designed with a differentiated topoisomerase I inhibitor payload, potentially offering benefits for patients with tumors resistant to MMAE-ADC. The drug targets tumors with both high and low Nectin-4 expression levels, supporting its development beyond urothelial carcinoma.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.69%
Tags
Rhea-AI Summary

Innate Pharma (Nasdaq: IPHA) has announced an upcoming investor and analyst event focused on its Antibody-Drug Conjugate (ADC) strategy, specifically highlighting IPH4502, their lead Nectin-4 antibody-drug candidate program. The hybrid event will take place in New York on February 5, 2025, from 10:00 a.m. to 12:00 p.m. EDT.

The company will present the latest scientific and clinical advancements related to Nectin-4 and its potential in cancer treatment. The event will be accessible both in-person and via webcast, with a replay available on Innate Pharma's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.44%
Tags
none
-
Rhea-AI Summary

Innate Pharma (Euronext Paris: IPH; Nasdaq: IPHA) has released its share and voting rights data as of December 31, 2024. The company reported 83,830,336 ordinary shares, along with 6,494 Preferred Shares 2016 and 7,581 Preferred Shares 2017.

The total number of theoretical voting rights stands at 84,585,576, which includes voting rights attached to AGAP 2016 (130 voting rights for AGAP 2016-1 and 111 for AGAP 2016-2). The total number of exercisable voting rights is 84,567,001, calculated excluding treasury shares. No voting rights are attached to AGAP 2017.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.76%
Tags
none
-
Rhea-AI Summary

Innate Pharma (Nasdaq: IPHA) announced a new growth strategy based on three key pillars: driving innovation with their proprietary ANKET® NK-cell engager Platform, accelerating development of Antibody-Drug Conjugates (ADCs), and advancing late-stage assets through partnerships.

The company is developing IPH6501, an ANKET® therapy currently in Phase 1/2 study for CD20-expressing non-Hodgkin's Lymphoma, and IPH4502, a topoisomerase I inhibitor ADC targeting Nectin-4 in Phase 1 trials for advanced solid tumors.

For late-stage assets, Innate is seeking partners for lacutamab in advanced T cell lymphomas, while monalizumab, partnered with AstraZeneca, is in Phase 3 PACIFIC-9 trial for non-small cell lung cancer with readouts expected by end of 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.28%
Tags
none
Rhea-AI Summary

Innate Pharma (Euronext Paris: IPH; Nasdaq: IPHA) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference taking place January 13-16, 2025, in San Francisco. CEO Jonathan Dickinson will present on Tuesday, January 14, 2025, from 11:15 - 11:55 am PST.

The company's executive team, including Dr Sonia Quaratino (EVP, Chief Medical Officer), Yannis Morel (EVP, Chief Operating Officer), and Arvind Sood (EVP, President of US Operations), will participate in 1x1 meetings during the conference. A live video webcast of the presentation will be available on the company's website under the 'Events' tab in the Investors section.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.09%
Tags
conferences

FAQ

What is the current stock price of Innate Pharma Sa (IPHA)?

The current stock price of Innate Pharma Sa (IPHA) is $2.38 as of May 8, 2025.

What is the market cap of Innate Pharma Sa (IPHA)?

The market cap of Innate Pharma Sa (IPHA) is approximately 205.5M.
Innate Pharma Sa

Nasdaq:IPHA

IPHA Rankings

IPHA Stock Data

205.51M
92.16M
0.3%
0.55%
Biotechnology
Healthcare
Link
France
Marseille